<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48440">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01715428</url>
  </required_header>
  <id_info>
    <org_study_id>LIRAGLUTIDE UNIPA</org_study_id>
    <nct_id>NCT01715428</nct_id>
  </id_info>
  <brief_title>Liraglutide and Cardio-Metabolic Risk Markers</brief_title>
  <official_title>Effects of Liraglutide on Cardio-Metabolic Risk Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Palermo</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incretin-based therapies have shown significant effects beyond those on glucose metabolism.
      We aim in the present study to evaluate the effects of liraglutide on several
      cardio-metabolic risk markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In details, we will evaluate the effects of liraglutide on carotid-intima media thickness,
      oxidative stress, ghrelin, heat shock proteins and lipoproteins.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>carotid intima-media thickness</measure>
    <time_frame>every four months for a total period of 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>carotid intima-media thickness will be assessed by doppler ultrasonography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in oxidative stress, ghrelin, atherogenic lipoproteins, heat shock proteins</measure>
    <time_frame>after 2 months of therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>oxidative stress, ghrelin, atherogenic lipoproteins, heat shock proteins will be measured by high-quality technologies</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type-2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <description>administration of liraglutide at 1.2 mg/daily</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult subjects with type-2 diabetes
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - patients with a diagnosis of type-2 diabetes

        Exclusion Criteria:

        - severe hepatic or renal diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Montalto, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Palermo, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manfredi Rizzo, MD, PhD</last_name>
    <phone>+390916552945</phone>
    <email>manfredi.rizzo@unipa.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfredi Rizzo, MD, PhD</last_name>
      <phone>+390916552945</phone>
      <email>manfredi.rizzo@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Manfredi Rizzo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 25, 2012</lastchanged_date>
  <firstreceived_date>October 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Palermo</investigator_affiliation>
    <investigator_full_name>Manfredi Rizzo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>diabetes, cardiovascular risk</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
